Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial.

Ilad Alavi DarazamKimia ForouharOmid Moradi Ali Saffaei Mahtabalsadat Mirjalili Zahra Sahraei

Published in: Iranian journal of pharmaceutical research : IJPR (2022)

Enoxaparin dose of 60 mg daily provided anti-factor Xa level higher than desired in most patients. In non-critically ill patients, the dose of 40 mg is the proper dose for thromboprophylaxis.

Keyphrases

venous thromboembolism
end stage renal disease
direct oral anticoagulants
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
physical activity
atrial fibrillation